Watch for Changes With Montelukast and Olopatadine Products

A new warning for montelukast (Singulair) and new olopatadine OTCs (Pataday) will bring changes to meds for seasonal allergies.

Singulair (montelukast) has a new boxed warning...since cases of mental health effects (depression, suicidal thoughts, etc) are still being reported despite prior precautions.

FDA now says that montelukast's benefits may NOT outweigh risks...especially for most patients with "hay fever."

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote